Efficacy and Safety of Vardenafil for the Treatment of Erectile Dysfunction in Men with Metabolic Syndrome: Results of a Randomized, Placebo-Controlled Trial

Authors


Tim Schneider, PUR/R, Praxisklinik Urologie Rhein-Ruhr, Schulstraße 11, D-45468 Mülheim, Germany. Tel: (49) 208 94067 900/-919; Fax: (49) 208 94067 915; E-mail: t.schneider@pur-r.de

ABSTRACT

Introduction.  The prevalence of erectile dysfunction (ED) is increased in men with metabolic syndrome compared with the general population.

Aim.  The aim of this study was to evaluate the efficacy and safety of vardenafil vs. placebo in men who had ED and metabolic syndrome.

Methods.  This was a 12-week, double-blind, randomized, multicenter, parallel-group, placebo-controlled prospective study in men with ED and metabolic syndrome (assessed by the International Diabetes Federation criteria). Vardenafil was administered at a starting dose of 10 mg, which could be titrated to 5 mg or 20 mg after 4 weeks, depending on efficacy and tolerability.

Main Outcome Measures.  Primary efficacy measures were the erectile function domain of the International Index of Erectile Function (IIEF-EF) and Sexual Encounter Profile (SEP) diary questions 2/3. Secondary efficacy measures included SEP1, a diary question assessing ejaculation, the percentage of men achieving “return-to-normal” erectile function, and the percentage of men who titrated to a different dose. Adverse events (AEs) were recorded throughout the study.

Results.  The intent-to-treat population included 145 men (vardenafil, N = 75; placebo, N = 70). Baseline least squares IIEF-EF domain scores were low (vardenafil: 12.0; placebo: 12.7), indicative of moderate-to-severe ED. Vardenafil was statistically significantly superior to placebo for all primary efficacy measures (P < 0.0001) and showed nominally statistically significant superiority compared with placebo for SEP1/ejaculation success rates (P = 0.0003 and P < 0.0001, respectively) and the percentage of subjects reporting “return-to-normal” erectile function (P = 0.0004). Treatment-emergent AEs were mild-to-moderate in severity and consistent with the known AE profile of phosphodiesterase type 5 inhibitors.

Conclusions.  This is the first study to assess the efficacy and safety of vardenafil, taken alone, for ED therapy in a population of men who all had metabolic syndrome. Although baseline erectile function in these patients was low, vardenafil treatment was associated with significant improvements in erectile function and rates of successful intercourse, and was well tolerated. Schneider T, Gleißner J, Merfort F, Hermanns M, Beneke M, and Ulbrich E. Efficacy and safety of vardenafil for the treatment of erectile dysfunction in men with metabolic syndrome: results of a randomized, placebo-controlled trial. J Sex Med 2011;8:2904–2911.

Ancillary